Accelerated infliximab induction therapy in inflammatory bowel disease

Authors

DOI:

https://doi.org/10.22516/25007440.1546

Keywords:

Inflammatory bowel diseases, infliximab, ulcerative colitis, Crohn’s disease, biological therapy

Abstract

Introduction: Inflammatory bowel disease (IBD), which includes ulcerative colitis (UC) and Crohn’s disease (CD), represents a therapeutic challenge, especially in moderate-to-severe cases and in patients with previous anti-TNF failure. Accelerated infliximab induction, using higher doses or shorter intervals than the standard regimen, has been proposed to achieve faster inflammatory control in patients with a high inflammatory burden or refractory disease. However, evidence in Latin American settings remains limited. The objective of this study was to describe the clinical outcomes of patients with IBD treated with accelerated infliximab induction at a Colombian referral center.

Methodology: Observational, descriptive case series that included adult and pediatric patients with UC or CD treated between January 2022 and December 2023 with infliximab 10 mg/kg at weeks 0, 1, and 2. The study evaluated clinical remission, the need for therapeutic escalation, and the requirement for surgery through a review of medical records.

Results: The study included five patients (four men; three adults and two pediatric patients), all with previous anti-TNF exposure. Three had UC and two had CD. Only one pediatric patient with CD achieved clinical remission. Four did not respond, three required a change in medication to tofacitinib or vedolizumab, and two underwent surgery. No serious adverse events were documented.

Conclusion: In this highly refractory cohort, accelerated induction showed a low remission rate and a frequent need for therapeutic escalation.

Downloads

Download data is not yet available.

Author Biographies

Viviana Parra-Izquierdo , Hospital Internacional de Colombia

Gastroenterologist and Rheumatologist, Center of Excellence for Inflammatory Bowel Disease, Hospital Internacional de Colombia, Bucaramanga, Colombia.

Sergio Romero Arias, Hospital Internacional de Colombia

Associate Physician, Center of Excellence for Inflammatory Bowel Disease, Hospital Internacional de Colombia, Bucaramanga, Colombia.

Carlos Cuadros, Hospital Internacional de Colombia

Pediatric Gastroenterologist, Center of Excellence for Inflammatory Bowel Disease and Pediatric Gastroenterology, Hospital Internacional de Colombia, Bucaramanga, Colombia.

Johon Garces, Hospital Internacional de Colombia

Pediatric Gastroenterologist, Center of Excellence for Inflammatory Bowel Disease and Pediatric Gastroenterology, Hospital Internacional de Colombia, Bucaramanga, Colombia.

Silvia Hoyos, Hospital Internacional de Colombia

Associate Physician, Center of Excellence for Inflammatory Bowel Disease, Hospital Internacional de Colombia, Bucaramanga, Colombia.

Ginary Orduz-Díaz, Hospital Internacional de Colombia

Head Nurse, Center of Excellence for Inflammatory Bowel Disease, Hospital Internacional de Colombia, Bucaramanga, Colombia.

Luis Felipe Murcia Cárdenas, Fundación Cardiovascular de Colombia

Internal Medicine Physician, Fundación Cardiovascular de Colombia, Bucaramanga, Colombia.

Cristian Florez Sarmiento, Hospital Internacional de Colombia

Associate Researcher, Cellular and Molecular Immunology Group (INMUBO), Universidad El Bosque, Bogotá; Center of Excellence for Inflammatory Bowel Disease and Gastroenterology, Hospital Internacional de Colombia, Bucaramanga, Colombia.

Juan Sebastián Frías Ordoñez, Hospital Internacional de Colombia

Gastroenterologist, Center of Excellence for Inflammatory Bowel Disease and Gastroenterology, Hospital Internacional de Colombia, Bucaramanga, Colombia.

References

Sokić-Milutinović A, Milosavljević T. Inflammatory Bowel Disease: From Conventional Immunosuppression to Biologic Therapy. Dig Dis. 2024;42(4):325–35. https://doi.org/10.1159/000535647

Cohn HM, Dave M, Loftus EV Jr. Understanding the Cautions and Contraindications of Immunomodulator and Biologic Therapies for Use in Inflammatory Bowel Disease. Inflamm Bowel Dis. 2017;23(8):1301–15. https://doi.org/10.1097/MIB.0000000000001199

Dong Y, Xu T, Xiao G, Hu Z, Chen J. Opportunities and challenges for synthetic biology in the therapy of inflammatory bowel disease. Front Bioeng Biotechnol. 2022;10:909591. https://doi.org/10.3389/fbioe.2022.909591

Triantafillidis JK, Zografos CG, Konstadoulakis MM, Papalois AE. Combination treatment of inflammatory bowel disease: Present status and future perspectives. World J Gastroenterol. 2024;30(15):2068–80. https://doi.org/10.3748/wjg.v30.i15.2068

Moreau J, Mas E. Drug resistance in inflammatory bowel diseases. Curr Opin Pharmacol. 2015;25:56–61. https://doi.org/10.1016/j.coph.2015.11.003

Li Y, Chen J, Bolinger AA, Chen H, Liu Z, Cong Y, et al. Target-based small molecule drug discovery towards novel therapeutics for inflammatory bowel diseases. Inflamm Bowel Dis. 2021;27 Suppl 2:S38–62. https://doi.org/10.1093/ibd/izab190

Feuerstein JD, Ho EY, Shmidt E, Singh H, Falck-Ytter Y, Sultan S, et al. AGA Clinical Practice Guidelines on the Medical Management of Moderate to Severe Luminal and Perianal Fistulizing Crohn’s Disease. Gastroenterology. 2021;160(7):2496–508. https://doi.org/10.1053/j.gastro.2021.04.022

Rubin DT, Ananthakrishnan AN, Siegel CA, Sauer BG, Long MD. ACG Clinical Guideline: Ulcerative Colitis in Adults. Am J Gastroenterol. 2019;114(3):384–413. https://doi.org/10.14309/ajg.0000000000000152

DailyMed. INFLECTRA (infliximab-dyyb) for injection, for intravenous use [Internet]. Bethesda (MD): U.S. National Library of Medicine; 2024 [consultado el 10 de septiembre de 2024]. Disponible en: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=37eaca10-d812-48bc-8b8e-b836bfa9968f

Kornbluth A, Sachar DB. Ulcerative colitis practice guidelines in adults: American College of Gastroenterology, Practice Parameters Committee. Am J Gastroenterol. 2010;105(3):501–23. https://doi.org/10.1038/ajg.2009.727

Steenholdt C, Coskun M, Buhl S, Bendtzen K, Ainsworth MA, Brynskov J, et al. Circulating cytokines and cytokine receptors in infliximab treatment failure due to TNF-α independent Crohn disease. Med (United States). 2016;95(16):e3417. https://doi.org/10.1016/j.medj.2016.09.002

Dreesen E, Faelens R, Van Assche G, Ferrante M, Vermeire S, Gils A, et al. Optimising infliximab induction dosing for patients with ulcerative colitis. Br J Clin Pharmacol. 2019;85(4):782–95. https://doi.org/10.1111/bcp.13859

Choy MC, Li Wai Suen CFD, Con D, Boyd K, Pena R, Burrell K, et al. Intensified versus standard dose infliximab induction therapy for steroid-refractory acute severe ulcerative colitis (PREDICT-UC): an open-label, multicentre, randomised controlled trial. Lancet Gastroenterol Hepatol. 2024;9(11):981-996. https://doi.org/10.1016/S2468-1253(24)00200-0

Gibson DJ, Heetun ZS, Redmond CE, Nanda KS, Keegan D, Byrne K, et al. An accelerated infliximab induction regimen reduces the need for early colectomy in patients with acute severe ulcerative colitis. Clin Gastroenterol Hepatol. 2015;13(2):330-335.e1. https://doi.org/10.1016/j.cgh.2014.07.041

Hindryckx P, Novak G, Vande Casteele N, Laukens D, Parker C, Shackelton LM, et al. Dose optimisation of infliximab for acute severe ulcerative colitis. Aliment Pharmacol Ther. 2017;45(5):617–30. https://doi.org/10.1111/apt.13913

Rutgeerts P, Sandborn WJ, Feagan BG, Reinisch W, Olson A, Johanns J, et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2005;353(23):2462-76. https://doi.org/10.1056/NEJMoa050516

Julião F, Márquez J, Aristizábal N, Yepes C, Zuleta J, Gisbert JP. Clinical efficacy of infliximab in moderate to severe ulcerative colitis in a Latin American referral population. Digestion. 2013;88(4):222–8. https://doi.org/10.1159/000355529

Balderramo D, Quaresma AB, Olivera PA, Savio MC, Villamil MPG, Panaccione R, et al. Challenges in the diagnosis and treatment of inflammatory bowel disease in Latin America. Lancet Gastroenterol Hepatol. 2024;9(3):263–72. https://doi.org/10.1016/S2468-1253(23)00421-5

Yamamoto-Furusho JK, Parra-Holguín NN, Julião-Baños F, Puentes F, López R, Bosques-Padilla F, et al. Clinical differentiation of inflammatory bowel disease (IBD) in Latin America and the Caribbean. Med (United States). 2022;101(3):E28624. https://doi.org/10.1097/MD.0000000000028624

World Medical Association. Declaration of Helsinki: Ethical principles for medical research involving human subjects. JAMA. 2013;310(20):2191–4. https://doi.org/10.1001/jama.2013.281053

Ministerio de Salud. Resolución Número 8430 de 1993, por la cual se establecen las normas científicas, técnicas y administrativas para la investigación en salud [Internet]. Colombia: MinSalud; 1993 [consultado el 10 de agosto de 2024]. Disponible en: https://www.minsalud.gov.co/sites/rid/lists/bibliotecadigital/ride/de/dij/resolucion-8430-de-1993.pdf

Sebastian S, Myers S, Nadir S, Subramanian S. Systematic Review: Efficacy and Safety of Accelerated Induction Regimes in Infliximab Rescue Therapy for Hospitalized Patients with Acute Severe Colitis. Dig Dis Sci. 2019;64(5):1119–28. https://doi.org/10.1007/s10620-018-5407-7

Govani SM, Berinstein JA, Waljee AK, Stidham RW, Higgins PDR, Hardiman KM. Use of Accelerated Induction Strategy of Infliximab for Ulcerative Colitis in Hospitalized Patients at a Tertiary Care Center. Dig Dis Sci. 2020;65(6):1800–5. https://doi.org/10.1007/s10620-019-05957-0

Table 1. Baseline clinical characteristics and short-term outcomes of patients undergoing accelerated infliximab induction (n = 5)

Published

2026-09-11

How to Cite

Parra-Izquierdo , V., Romero Arias, S., Cuadros, C., Garces, J., Hoyos, S., Orduz-Díaz, G., … Frías Ordoñez, J. S. (2026). Accelerated infliximab induction therapy in inflammatory bowel disease. Revista Colombiana De Gastroenterología, 41(3), 309–315. https://doi.org/10.22516/25007440.1546

Issue

Section

Originals articles

Altmetric

Escanea para compartir
QR Code
Crossref Cited-by logo
Article metrics
Abstract views17
Galley views6
PDF Views6
HTML views0
Other views0

Some similar items: